Dossier
Foundation for Angelman Syndrome Therapeutics
Coverage of Foundation for Angelman Syndrome Therapeutics in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is reducing its $2.67 billion investment in Germany's weight-loss syringe production due to new cost-cutting laws, and Boehringer Ingelheim is cutting $1 billion in German investments amid sector uncertainty. U.S. FDA Acting Commissioner Kyle Diamantas is engaging rare disease groups to address concerns raised by his predecessor's policies.